215 related articles for article (PubMed ID: 24399735)
1. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Szałek E; Karbownik A; Grabowski T; Sobańska K; Wolc A; Grześkowiak E
Pharmacol Rep; 2013; 65(5):1383-90. PubMed ID: 24399735
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not?
Szałek E; Karbownik A; Połom W; Matuszewski M; Sobańska K; Urjasz H; Grabowski T; Wolc A; Grześkowiak E
Pharmacol Rep; 2012; 64(6):1554-9. PubMed ID: 23406766
[TBL] [Abstract][Full Text] [Related]
3. The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits.
Szałek E; Karbownik A; Sobańska K; Połom W; Grabowski T; Wolc A; Matuszewski M; Grześkowiak E
Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2393-9. PubMed ID: 25219843
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits.
Szałek E; Karbownik A; Sobańska K; Grabowski T; Połom W; Lewandowska M; Wolc A; Matuszewski M; Grześkowiak E
Pharmacol Rep; 2014 Oct; 66(5):892-6. PubMed ID: 25149997
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetic interaction between levofloxacin and sunitinib.
Czyrski A; Kondys K; Szałek E; Karbownik A; Grześkowiak E
Pharmacol Rep; 2015 Jun; 67(3):542-4. PubMed ID: 25933967
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Houk BE; Bello CL; Kang D; Amantea M
Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
[TBL] [Abstract][Full Text] [Related]
7. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
Haznedar JO; Patyna S; Bello CL; Peng GW; Speed W; Yu X; Zhang Q; Sukbuntherng J; Sweeny DJ; Antonian L; Wu EY
Cancer Chemother Pharmacol; 2009 Sep; 64(4):691-706. PubMed ID: 19169880
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.
Phillips ST; Nagaro K; Sambol SP; Johnson S; Gerding DN
Anaerobe; 2011 Aug; 17(4):166-9. PubMed ID: 21511046
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Dajcs JJ; Thibodeaux BA; Marquart ME; Girgis DO; Traidej M; O'Callaghan RJ
Antimicrob Agents Chemother; 2004 Jun; 48(6):1948-52. PubMed ID: 15155183
[TBL] [Abstract][Full Text] [Related]
10. Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea.
Cho Y; Park HS
BMJ Open; 2018 Sep; 8(9):e020974. PubMed ID: 30269062
[TBL] [Abstract][Full Text] [Related]
11. The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits.
Sobańska K; Karbownik A; Szałek E; Płotek W; Grabowski T; Szewczyk A; Marcinkowska D; Połom W; Matuszewski M; Grześkowiak E
Eur Rev Med Pharmacol Sci; 2016; 20(1):166-73. PubMed ID: 26813470
[TBL] [Abstract][Full Text] [Related]
12. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
[TBL] [Abstract][Full Text] [Related]
13. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Etienne-Grimaldi MC; Renée N; Izzedine H; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3757-61. PubMed ID: 19797000
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
[TBL] [Abstract][Full Text] [Related]
15. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Kloth JS; Binkhorst L; de Wit AS; de Bruijn P; Hamberg P; Lam MH; Burger H; Chaves I; Wiemer EA; van der Horst GT; Mathijssen RH
Clin Pharmacokinet; 2015 Aug; 54(8):851-8. PubMed ID: 25647628
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice.
Liew MH; Ng S; Chew CC; Koo TW; Chee YL; Chee EL; Modamio P; Fernández C; Mariño EL; Segarra I
Invest New Drugs; 2017 Apr; 35(2):145-157. PubMed ID: 28070719
[TBL] [Abstract][Full Text] [Related]
18. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin.
García-Sáenz MC; Arias-Puente A; Fresnadillo-Martinez MJ; Carrasco-Font C
J Cataract Refract Surg; 2001 Dec; 27(12):1969-74. PubMed ID: 11738912
[TBL] [Abstract][Full Text] [Related]
19. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
Wagner RS; Abelson MB; Shapiro A; Torkildsen G
Arch Ophthalmol; 2005 Sep; 123(9):1282-3. PubMed ID: 16157821
[No Abstract] [Full Text] [Related]
[Next] [New Search]
